New hope for arthritis sufferers: experimental drug shows promise in Late-Stage trial
Disease control
Ongoing
This study tests a new oral drug called LNK01001 (Zemprocitinib) in 430 adults with moderate-to-severe rheumatoid arthritis who have not improved with other biologic treatments. Participants receive either the drug or a placebo for 24 weeks, followed by a long-term safety extensi…
Phase: PHASE3 • Sponsor: Lynk Pharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC